We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Metabolism-Based Blood Test to Detect Multiple Cancer Types Prior to Symptoms

By LabMedica International staff writers
Posted on 22 Jun 2022

A pioneering metabolism-based liquid biopsy could detect any-type cancer in adults who show no symptoms or have any recent history of cancer, thereby preventing cancer mortality through early detection. More...

Elypta (Stockholm, Sweden), which aims to commercialize the first metabolism-based liquid biopsy for early detection of any cancer, will develop and validate blood and urine tests for Multi-Cancer Early Detection (MCED) in adults with no symptoms of cancer and for detection of recurrence in kidney cancer patients. The tests are based on the exhaustive profiling of human glycosaminoglycans - also known as the GAGome - as biomarkers of cancer metabolism, an approach pioneered by Elypta.

Metabolic reprogramming is a hallmark of cancer. Cancer cells need to rewire the way they procure energy and nutrients to support abnormal proliferation and growth. Yet, metabolism is an under-investigated layer of information to identify biomarkers for cancer. By overlaying genome-wide omics data onto the largest reconstruction of the human metabolic network, Elypta identified the profile of the GAGome as the most deregulated panel of metabolites in cancer.

Recent evidence suggests that metabolic reprogramming of GAGomes is a ubiquitous process in cancers. In a clinical study with over 1500 samples across 14 cancer types, a multi-cancer GAGome signature was detected in the plasma and urine that was significantly elevated already in stage I in every cancer type tested. Preclinical evidence in mice supports a causal link between cancer initiation and changes in the GAGome providing mechanistic insight on its value for early detection.

“Our MCED test has the potential to greatly increase the share of cancers detected at the earliest stages when treatment could mean a cure besides being less costly,” said Francesco Gatto, CSO & Founder of Elypta. “Detecting stage I cancer is the key challenge here, and whereas other MCED tests based on cell free DNA struggle to find cancer at this early stage, metabolism-based biomarkers could really make a difference.”

Related Links:
Elypta 


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
New
Alpha-Fetoprotein Reagent
AFP Reagent Kit
New
Varicella Zoster Test
ZEUS ELISA Varicella Zoster IgG Test System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The POC device rapidly predicts neonatal respiratory disease at birth in the NICU (Photo courtesy of SIME Diagnostics)

AI-Powered Lung Maturity Test Identifies Newborns at Higher Risk of Respiratory Distress

Each year, approximately 300,000 babies in the United States are born between 32 and 36 weeks' gestation, according to national health data. This group is at an elevated risk for respiratory distress,... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: Custom hardware and software for the real-time detection of immune cell biophysical signatures in NICU (Photo courtesy of Pediatric Research, DOI:10.1038/s41390-025-03952-y)

First-Of-Its-Kind Device Profiles Newborns' Immune Function Using Single Blood Drop

Premature infants are highly susceptible to severe and life-threatening conditions, such as sepsis and necrotizing enterocolitis (NEC). Newborn sepsis, which is a bloodstream infection occurring in the... Read more

Pathology

view channel
Image: Results of AI-based 3D virtual H&E staining and quantitative analysis of pathological tissue (Photo courtesy of Nature Communications, DOI:10.1038/s41467-025-59820-0)

Virtual Staining Technology Paves Way for Non-Invasive Pathological Diagnosis

For more than 200 years, traditional pathology has depended on the technique of examining cancer tissues under a microscope, a method that provides only limited, specific cross-sections of the 3D structure... Read more

Technology

view channel
Image: Concept of biosensor integrated into hygiene pads enabling direct semi-quantitative analysis of biomarkers in unprocessed menstruation blood (Photo courtesy of Dosnon, L et al. DOI: 10.1002/advs.202505170)

First Ever Technology Recognizes Disease Biomarkers Directly in Menstrual Blood in Sanitary Towels

Over 1.8 billion people menstruate worldwide, yet menstrual blood has been largely overlooked in medical practice. This blood contains hundreds of proteins, many of which correlate with their concentration... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.